Radioimmunotherapy Market By Product Type (Monoclonal Antibodies, Radiopharmaceuticals); By Application (Cancer Treatment, Diagnostic Imaging); By End-User (Hospitals & Oncology Centers, Pharmaceutical & Biotech Companies, Research Institutions, Contract Research Organizations); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Radioimmunotherapy Market: Pretargeted Platforms Revive Antibody-Guided Radiation Beyond CD20 Lymphoma (Last Updated on: June-2026)

The Global Radioimmunotherapy Market is set to grow at a CAGR of 7.2%, valued at USD 1.6 billion in 2024 and projected to reach USD 2.8 billion by 2030.

 

The Radioimmunotherapy Market represents a specialized segment within targeted oncology and nuclear medicine. Radioimmunotherapy, or RIT, combines the antigen-recognition ability of monoclonal antibodies with the cell-killing effect of radioactive isotopes. The antibody component binds to a tumor-associated antigen, while the radionuclide delivers radiation directly to malignant cells and nearby tumor tissue. This differentiates RIT from conventional external-beam radiation therapy as well as standard monoclonal antibody approaches, as it functions as antibody-directed internal radiation delivery.

 

The market also has a distinct clinical history, as radioimmunotherapy is not a novel or unvalidated concept. Zevalin and Bexxar established FDA-approved radioimmunotherapy in CD20-positive B-cell non-Hodgkin lymphoma more than two decades ago. Yet broad adoption remained limited because treatment required coordination between hematology, oncology, nuclear medicine, radiopharmacy, radiation safety, and reimbursement workflows. Bexxar was later withdrawn from the commercial market, while Zevalin remains available but is used in a narrow lymphoma population.

 

The current market is best characterized as an approved yet underutilized therapy category, supported by renewed momentum from ongoing pipeline development. The legacy base is CD20-directed beta-emitting RIT for lymphoma. The next phase is being shaped by alpha-emitting radionuclides, pretargeted radioimmunotherapy, nanobody-based radiotherapeutics, CD38-targeted lymphoma programs, CD33-targeted AML approaches, and solid tumor-directed antibody or protein carriers. The market is no longer focused solely on the clinical efficacy of radiolabeled antibodies. The key consideration has shifted to whether next-generation platforms can improve tumor-to-normal tissue dose ratios, reduce hematologic toxicity, streamline treatment workflows, and expand the application of radioimmunotherapy beyond low-grade lymphomas.

 

Approved Therapy Base and Clinical Positioning

Zevalin, or yttrium-90 ibritumomab tiuxetan, remains the core FDA-approved RIT therapy. It is a CD20-directed radiotherapeutic antibody used in adult patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma. It is also approved for previously untreated follicular NHL patients who achieve a partial or complete response to first-line chemotherapy. Zevalin links an anti-CD20 monoclonal antibody to yttrium-90, allowing radiation to be delivered directly to CD20-positive B cells and surrounding malignant tissue.

Bexxar, or iodine-131 tositumomab, was another CD20-directed radioimmunotherapy approved for relapsed or refractory CD20-positive non-Hodgkin lymphoma. It used iodine-131 attached to an anti-CD20 antibody and required a dosimetric step before therapeutic administration. Although Bexxar provided important clinical validation for the class, it was withdrawn from the commercial market in 2014 after low utilization. Its withdrawal remains an important lesson for the market, highlighting that strong clinical biology does not necessarily translate into adoption when the delivery model is operationally complex.

Accordingly, the approved RIT base remains limited in scope but clinically significant. Both Zevalin and Bexxar demonstrated the feasibility of delivering targeted radiation to lymphoma cells using radiolabeled antibodies. However, limitations extended beyond clinical efficacy to the broader treatment ecosystem. Community oncologists often needed to refer patients to nuclear medicine specialists, while nuclear medicine physicians were not consistently integrated into lymphoma care pathways. In addition, reimbursement structures, radioactive handling requirements, scheduling complexity, and limited physician familiarity significantly influenced real-world adoption.

This historical context gives the current market a distinct profile. Unlike emerging radiopharmaceutical segments driven primarily by new approvals, RIT is re-establishing its role in oncology through advances in technology and workflow optimization. Future opportunities are less about direct replication of Zevalin or Bexxar and more focused on next-generation platforms that decouple targeting from payload delivery, incorporate short-range alpha emitters, enhance tumor retention, and minimize normal tissue exposure.

 

Radioimmunotherapy Market Segment Analysis

By product type, monoclonal antibody–based radioimmunotherapy continues to represent the foundational segment of the market. This segment includes therapies that use antibodies to recognize tumor antigens and carry radionuclides directly to malignant cells. CD20-directed therapies in lymphoma represent the most well-established example within approved CD antigen–targeted treatment. The most relevant patient pool remains B-cell non-Hodgkin lymphoma, which is expected to account for 79,320 new U.S. cases in 2026. This disease base is directly relevant because approved RIT products historically targeted CD20-positive B-cell NHL. However, the segment’s future depends on new targets such as CD38, CD33, HER2, PD-L1, and DLL3, rather than a return to CD20 alone.

Radiopharmaceutical platforms constitute the most innovation-intensive segment of the market. The market is shifting from earlier beta-emitting RIT toward alpha-emitting and pretargeted systems. Yttrium-90 and iodine-131 created the approved base, but actinium-225, lead-212, and lutetium-177 payload systems are driving much of the new development. Alpha emitters are attractive because they deliver high-energy radiation over a short path length, which may be useful for micrometastatic disease, resistant tumors, and antigen-positive cells close to sensitive normal tissue. The challenge is balancing potency with marrow safety, isotope availability, manufacturing reliability, and dosimetry.

By application, oncology remains the primary area of clinical use. Hematologic malignancies are still the most established application because lymphoma cells are radiosensitive, CD antigens are well defined, and malignant cells are more accessible than many solid tumor targets. Non-Hodgkin lymphoma remains the historical anchor, while acute myeloid leukemia is an important pipeline setting for CD33-directed alpha therapy. In the U.S., acute myeloid leukemia is expected to account for 22,720 new cases in 2026, which supports continued interest in targeted radiotherapeutic strategies for patients with limited options after relapse or induction failure.

Solid tumors are emerging as a key growth area for future therapeutic development. RIT development in solid tumors has historically been limited by poor antibody penetration, heterogeneous antigen expression, slow blood clearance, and normal tissue exposure. Newer platforms are trying to address these barriers through smaller carriers, nanobodies, pretargeting, and alpha-emitting payloads. Lung cancer is especially relevant for next-generation radiotherapeutic exploration. The U.S. is expected to record 229,410 new lung and bronchus cancer cases in 2026, and small cell lung cancer accounts for about 10% to 15% of lung cancers. This is clinically relevant as DLL3- and PD-L1–targeted radiotherapeutic approaches are being evaluated in aggressive lung cancer settings.

 

What Is Moving RIT Adoption

Renewed interest in targeted radiopharmaceutical therapy represents a key growth catalyst. The clinical uptake of PRRT and PSMA-directed radioligand therapy has strengthened oncologist familiarity with internally delivered, molecularly targeted radiation. While these modalities are distinct from radioimmunotherapy (RIT), they have contributed to the development of nuclear medicine and radiopharmacy infrastructure that supports broader RIT adoption.

Alpha-emitter development is another important growth driver. Earlier RIT approaches were predominantly based on beta-emitting radionuclides, whereas alpha emitters such as actinium-225 and lead-212 offer higher linear energy transfer and shorter path length, potentially improving tumor cell kill while limiting off-target exposure. However, clinical translation continues to depend on evidence related to dose optimization, organ toxicity, isotope supply constraints, and feasibility of repeat dosing.

Pretargeted radioimmunotherapy represents a further evolution in delivery design. Conventional RIT is limited by prolonged circulation of radiolabeled antibodies and associated normal tissue exposure. Pretargeting decouples tumor binding from payload delivery by administering a tumor-targeting construct first, followed by a radiolabeled component after clearance of unbound agents. This approach is intended to improve tumor-to-normal tissue uptake ratios and reduce systemic toxicity, potentially addressing a key limitation that historically constrained adoption.

Expansion into resistant disease settings is also shaping clinical utilization. RIT is being evaluated in indications with high unmet need, including relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, treatment-resistant solid tumors, PD-L1-positive non-small cell lung cancer, high-grade neuroendocrine tumors, and neuroendocrine prostate cancer. These settings are particularly relevant given RIT’s distinct mechanism of action compared with chemotherapy, immune checkpoint inhibition, and conventional antibody therapies.

 

Pipeline and Innovation Landscape

The current radioimmunotherapy pipeline is more diversified than the approved treatment landscape suggests. While CD20-directed lymphoma therapies form the established commercial foundation, emerging programs are expanding into CD38, CD33, PD-L1, DLL3, HER2, and other tumor-associated targets.

A key development driver is the advancement of pretargeted radioimmunotherapy approaches. For example, Y-mAbs’ CD38-SADA program is evaluating a two-step strategy in relapsed or refractory non-Hodgkin lymphoma, in which the CD38-SADA construct first binds to lymphoma cells, followed by administration of a lutetium-177 DOTA payload that selectively targets tumor-bound constructs. This approach is designed to maintain targeting specificity while reducing off-target radiation exposure to normal tissues.

CD33-directed alpha therapy represents a key area of development. Actimab-A, an actinium-225–conjugated anti-CD33 antibody (lintuzumab), is being evaluated in relapsed or refractory acute myeloid leukemia. Although CD33 is a biologically rational AML target, its therapeutic window is narrow due to expression on normal hematopoietic cells. As a result, dose optimization, marrow recovery dynamics, combination sequencing, and transplantation timing remain central to clinical development.

Nanobody-based radiotherapeutics are expanding the radiotherapy–immunotherapy interface into solid tumors. RAD 204 is a PD-L1–targeted nanobody radiotherapeutic under investigation in non-small cell lung cancer. Compared with conventional antibodies, smaller targeting constructs may enable faster tumor penetration and more rapid systemic clearance, potentially improving both imaging and therapeutic feasibility in solid tumors. Although still in early development, this approach aligns with the broader market shift toward smaller targeting carriers and more precise biodistribution.

DLL3-directed radiopharmaceutical research is another important solid tumor signal. DLL3 is highly expressed in small cell lung cancer and neuroendocrine prostate cancer, making it attractive for aggressive tumors with limited durable treatment options. DLL3-targeted alpha radiotherapeutics are not classic approved RIT products today, but they show where antibody, protein, and radioligand platforms may converge in neuroendocrine-like cancers.

AlphaMedix, or lead-212 DOTAMTATE, should be positioned with appropriate distinction from conventional antibody-based radioimmunotherapy, as it is a peptide receptor–targeted radioligand therapy for somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. However, its FDA Breakthrough Therapy Designation in 2024 remains relevant to the broader radiopharmaceutical landscape, reflecting growing regulatory interest in targeted alpha therapy and supporting infrastructure development that may also benefit antibody-guided radionuclide approaches.

 

North America Radioimmunotherapy Market

North America, led by the United States, represents the most clinically advanced region in the radiopharmaceutical therapy (RIT) market, supported by a history of FDA-approved RIT products, well-developed nuclear medicine infrastructure, strong hematologic oncology expertise, and an expanding radiopharmaceutical development ecosystem.

The most clinically relevant U.S. patient population is concentrated in hematologic malignancies and selected solid tumor indications. Non-Hodgkin lymphoma is expected to account for 79,320 new U.S. cases in 2026, directly supporting the historical CD20 RIT base. AML is expected to account for 22,720 new U.S. cases in 2026, which is relevant to CD33-targeted alpha therapy. Lung and bronchus cancer is expected to account for 229,410 new U.S. cases in 2026, while small cell lung cancer represents about 10% to 15% of lung cancers. These figures explain why RIT development is moving from lymphoma into AML and solid tumor radiotherapeutics rather than staying confined to CD20 lymphoma.

Adoption in North America is primarily driven by treatment-system readiness. RIT requires nuclear medicine physicians, hematologists, medical oncologists, radiopharmacists, radiation safety officers, trained infusion teams, blood count monitoring, dosimetry support, and isotope scheduling. This keeps treatment concentrated in academic medical centers, comprehensive cancer centers, and hospitals with mature nuclear medicine programs.

The region also benefits from the broader rise of radioligand therapy. PRRT and PSMA radioligand therapy have expanded institutional familiarity with radiopharmaceutical handling, patient selection, radiation precautions, and oncology-nuclear medicine coordination. This infrastructure does not solve all RIT adoption barriers, but it gives newer RIT programs a stronger delivery environment than Zevalin and Bexxar had during their early commercial years.

 

Recent Developmental Direction in the Radioimmunotherapy Market

In 2024, renewed clinical discussion around RIT focused on how antibody-guided radiation could re-enter oncology through better payloads, better targeting systems, and more practical workflows. Oncology Nurse Advisor highlighted RIT as a treatment approach that combines radiation and immunotherapy, reflecting renewed clinical interest in targeted radiation strategies rather than conventional broad-field radiation alone.

In February 2024, AlphaMedix received FDA Breakthrough Therapy Designation for unresectable or metastatic progressive SSTR-expressing GEP-NETs in PRRT-naïve patients. Although this is peptide-targeted alpha therapy rather than classic RIT, it is a relevant radiopharmaceutical signal because it supports clinical momentum around targeted alpha radiation.

In April 2025, Y-mAbs dosed the first patient in a Phase 1 trial of CD38-SADA pretargeted radioimmunotherapy in relapsed or refractory non-Hodgkin lymphoma. This is one of the most relevant RIT-specific freshness signals because it tests whether a two-step pretargeted design can improve tumor selectivity and reduce normal tissue radiation exposure.

In 2025, Actimab-A continued advancing as a CD33-directed actinium-225 radiotherapeutic for relapsed or refractory AML. Its development is important because AML remains a difficult myeloid malignancy with high relapse risk and limited durable options for many patients. CD33 alpha therapy also shows how RIT can move beyond lymphoma into myeloid disease.

In 2024 and 2025, PD-L1 nanobody-based radiotherapeutic development gained attention in non-small cell lung cancer through RAD 204. This supports the broader move from full-length antibody RIT toward smaller targeting constructs that may penetrate tumors faster and clear from circulation more efficiently.

DLL3-directed alpha radiopharmaceutical work is also gaining momentum in high-grade neuroendocrine tumors, small cell lung cancer, and neuroendocrine prostate cancer. This is important because these tumor types are aggressive, often relapse after standard therapy, and may benefit from highly targeted radiation if antigen expression and dosimetry are favorable.

 

Evolving Market Landscape

The Radioimmunotherapy Market is entering a second phase of development. The initial phase was characterized by CD20-targeted beta-emitting therapies in lymphoma, while the emerging phase is being driven by alpha-emitting isotopes, pretargeting strategies, nanobody-based platforms, smaller protein carriers, and expansion into solid tumor indications.

Future market evolution will not be defined by replication of the Zevalin and Bexxar treatment model. Future adoption will depend on whether next-generation platforms can demonstrate clear clinical advantages, including improved tumor-to-normal tissue selectivity, reduced systemic exposure, manageable hematologic toxicity, simplified workflows, and better integration into established oncology treatment pathways.

Hematologic malignancies will remain the most clinically grounded application because the approved RIT base is in B-cell NHL and the pipeline includes CD38 and CD33 programs. Solid tumors will define the upside. Lung cancer, neuroendocrine-like tumors, prostate cancer variants, HER2-positive disease, and other antigen-defined cancers may become more relevant as nanobodies, alpha emitters, and pretargeting platforms mature.

Overall, the Radioimmunotherapy Market should be positioned as a targeted radiopharmaceutical oncology market with a validated but underused approved base and a technically stronger pipeline. Its value lies in linking antibody or protein targeting with radionuclide delivery. The next phase will depend on whether newer RIT platforms can overcome the workflow and toxicity issues that limited legacy products while benefiting from the broader theranostics infrastructure now expanding across oncology.

 

Radioimmunotherapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.6 Billion
Revenue Forecast in 2030	USD 2.8 Billion
Overall Growth Rate	CAGR of 7.2% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, By Application, By End-User, By Geography
By Product Type	Monoclonal Antibodies, Radiopharmaceuticals
By Application	Cancer Treatment, Diagnostic Imaging
By End User	Hospitals & Oncology Centers, Pharmaceutical & Biotech Companies, Research Institutions, Contract Research Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, China, India, Brazil, Japan, and others
Market Drivers	- Rising cancer incidence - Increasing adoption of precision medicine - Advancements in radiopharmaceuticals
Customization Option	Available upon request